Publications by authors named "Mark Reding"

Claim this Profile
N
New therapies in hemophilia: extend the half-life, mimic, or rebalance?
Mark T Reding

Hematology Am Soc Hematol Educ Program· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergent laparoscopic cholecystectomy is safe in the setting of hereditary coagulation disorders: a propensity score-matched analysis of the Nationwide Readmissions Database.
Sean H Nguyen, Colin Tang-Whitmore, Zoe Randall, Jordan Sauve, Pravin Meshram, Mark Reding

J Gastrointest Surg· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and management of patients with hereditary factor X deficiency: A case series.
Meera Chitlur, Lauren E Amos, Mark T Reding, Cynthia Sabo, Suchitra S Acharya

Transfusion· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM-POWR Study.
Mark T Reding, María Teresa Alvarez Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita

Eur J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.
Mark T Reding, Shadan Lalezari, Gili Kenet, Giovanni Di Minno, Jonathan Ducore

Drugs R D· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII.
Mark T Reding, Mindy Simpson, Jonathan Ducore, Pål Andrè Holme, Monika Maas Enriquez

Acta Haematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant factor VIIa: new insights into the mechanism of action through product innovation.
Miguel A Escobar, Maureane Hoffman, Giancarlo Castaman, Cedric Hermans, Johnny Mahlangu, Mark T Reding

Res Pract Thromb Haemost· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.
Mark T Reding, Shadan Lalezari, Gili Kenet, Giovanni Di Minno, Jonathan Ducore

Drugs R D· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.
Bella Madan, Margareth C Ozelo, Priyanka Raheja, Emily Symington, Doris V Quon, Mark T Reding

J Thromb Haemost· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of obesity on chronic pain in patients with haemophilia: A multicentre retrospective analysis.
Keerthy Joseph, Adam Cuker, Skye Peltier, Mark T Reding, Dunlei Cheng

Haemophilia· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A.
Mark T Reding, María Teresa Álvarez-Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita

Eur J Haematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: analysis from the PROTECT VIII study.
Mark T Reding, Ingrid Pabinger, Pål Andrè Holme, Monika Maas Enriquez, Maria Elisa Mancuso

Ther Adv Hematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia.
Duc Q Tran, Craig C Benson, Judith A Boice, Meera Chitlur, Amy L Dunn, Mark T Reding

Expert Rev Hematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
Johnny Mahlangu, Radoslaw Kaczmarek, Annette von Drygalski, Susan Shapiro, Sheng-Chieh Chou, Mark T Reding

N Engl J Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature.
Alfonso Iorio, Christoph Königs, Mark T Reding, Dawn Rotellini, Mark W Skinner

Haemophilia· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A laparoscopic approach to address massive splenomegaly, symptomatic cholelithiasis, and a planned postoperative pregnancy: A case report.
Alexandra A Bishop, Eric Krohn, Victor R Vakayil, Kyle Pribyl, Mark T Reding

Clin Case Rep· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective.
Cedric Hermans, Mark T Reding, Jan Astermark, Robert Klamroth, Maria Elisa Mancuso

Crit Rev Oncol Hematol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies.
Adam J Kanack, Bandana Singh, Gemlyn George, Krishna Gundabolu, Scott A Koepsell, Mark Reding

Am J Hematol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study.
Gili Kenet, Yeu-Chin Chen, Gillian Lowe, Charles Percy, Huyen Tran, Mark Reding

J Clin Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study.
Surbhi Shah, Sean Switzer, Nathan D Shippee, Pamela Wogensen, Kathryn Kosednar, Mark Reding

JMIR Med Inform· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
Miguel Escobar, James Luck, Yevhenii Averianov, Jonathan Ducore, Maria Fernanda López Fernández, Mark T Reding

Haemophilia· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders.
Leonard A Valentino, Judith R Baker, Regina Butler, Miguel Escobar, Neil Frick, Mark T Reding

J Blood Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
Maria Elisa Mancuso, Mark T Reding, Claude Negrier, Bryce A Kerlin, Savita Rangarajan

Thromb Haemost· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A.
Elena Santagostino, Shadan Lalezari, Mark T Reding, Jonathan Ducore, Heng Joo Ng

Haemophilia· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study.
Mark T Reding, Ingrid Pabinger, Pal Andre Holme, Lone Poulsen, Claude Negrier

Haemophilia· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis